Chinese General Practice ›› 2023, Vol. 26 ›› Issue (05): 541-549.DOI: 10.12114/j.issn.1007-9572.2022.0549
Special Issue: 心力衰竭最新文章合集; 心房颤动最新文章合集; 心血管最新文章合集
• Original Research • Previous Articles Next Articles
Received:
2022-06-11
Revised:
2022-08-15
Published:
2023-02-15
Online:
2022-11-25
Contact:
XIAO Hua
通讯作者:
肖骅
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0549
组别 | 例数 | 男性〔n(%)〕 | 合并基础疾病〔n(%)〕 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
冠心病 | 高血压 | 糖尿病 | 左心室肥厚 | 心肌病 | 肝功能不全 | 慢性肾脏病 | 周围动脉疾病 | 贫血 | 甲状腺功能亢进症 | 慢性阻塞性肺疾病 | |||
<65岁组 | 691 | 332(48.0)b | 218(31.5)b | 212(30.7)b | 107(15.5) | 76(11.0) | 87(12.6) | 16(2.3) | 49(7.1)b | 8(1.2)b | 34(4.9)b | 49(7.1) | 45(6.5)b |
65~75岁组 | 1 328 | 616(46.4)b | 825(62.1)b | 640(48.2)b | 241(18.1) | 232(17.5) | 95(7.2)c | 29(2.2) | 116(8.7)b | 22(1.7)b | 70(5.3)b | 35(2.6) | 191(14.4)b |
>75岁组 | 1 992 | 784(39.4) | 1 567(78.7) | 1 195(60.0) | 352(17.7) | 497(24.9) | 29(1.5)c | 24(1.2) | 278(14.0) | 77(3.9) | 213(10.7) | 34(1.7) | 381(19.1) |
检验统计量值 | 24.095 | 508.676 | 182.784 | 2.368 | 70.613 | 141.901 | 6.266 | 35.387 | 22.302 | 42.383 | 52.742 | 64.241 | |
P值 | <0.001 | <0.001 | <0.001 | 0.306 | <0.001 | <0.001 | 0.044 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 瓣膜性心房颤动〔n(%)〕 | 心房颤动类型〔n(%)〕 | 心功能分级〔n(%)〕 | CHA2DS2-VASc评分( | HAS-BLED评分( | LAD( | |||||||
阵发性心房颤动 | 持续性心房颤动 | 长程持续性心房颤动 | 心功能Ⅱ级 | 心功能Ⅲ~Ⅳ级 | |||||||||
<65岁组 | 273(39.5) | 125(18.1) | 405(58.6) | 161(23.3) | 175(25.4) | 516(74.6) | 2.28±1.09 | 0.72±0.81 | 42.42±7.90b | ||||
65~75岁组 | 268(20.2)c | 229(17.2) | 772(58.1) | 327(24.6) | 356(26.8) | 972(73.2) | 3.59±1.18 | 1.86±0.83 | 44.73±9.40b | ||||
>75岁组 | 124(6.2)c | 396(19.9) | 1 066(53.5) | 530(26.6) | 421(21.1) | 1 571(78.8) | 4.75±1.19 | 1.98±0.83 | 47.95±10.97 | ||||
检验统计量值 | 429.531 | 9.903 | 15.332 | 1234.844a | 632.185a | 97.334a | |||||||
P值 | <0.001 | 0.042 | 0.001 | <0.001 | <0.001 | <0.001 | |||||||
组别 | LVIDd( | LVEF( | 心力衰竭类型〔n(%)〕 | 华法林〔n(%)〕 | NOAC | 阿司匹林〔n(%)〕 | |||||||
HFrEF | HFmrEF | HFpEF | 达比加群〔n(%)〕 | 利伐沙班〔n(%)〕 | |||||||||
<65岁组 | 46.48±9.59 | 51.85±12.92 | 140(20.3) | 156(22.5) | 395(57.2)b | 386(55.9) | 22(3.2) | 30(4.3) | 76(11.0) | ||||
65~75岁组 | 49.83±9.91 | 52.60±12.50 | 221(16.6) | 297(22.4) | 810(61.0)b | 563(42.4)c | 61(4.6) | 55(4.1) | 236(17.8) | ||||
>75岁组 | 51.52±10.45 | 56.11±10.86 | 171(8.6) | 369(18.5) | 1 452(72.9) | 567(28.5)c | 99(5.0) | 108(5.4) | 351(17.6) | ||||
检验统计量值 | 82.112a | 51.890a | 404.542 | 181.650 | 3.793 | 3.254 | 18.523 | ||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.150 | 0.197 | <0.001 | ||||||
组别 | 氯吡格雷〔n(%)〕 | 其他抗血小板药物〔n(%)〕 | 双联抗血小板〔n(%)〕 | 心室率控制药物〔n(%)〕 | β-受体阻滞剂〔n(%)〕 | 地高辛〔n(%)〕 | ARB/ACEI类〔n(%)〕 | 他汀类〔n(%)〕 | 转律治疗〔n(%)〕 | 导管消融〔n(%)〕 | |||
<65岁组 | 73(10.6) | 2(0.3) | 21(3.0) | 600(86.8) | 476(68.9) | 174(25.2) | 332(48.1) | 241(34.9) | 40(5.8) | 11(1.6) | |||
65~75岁组 | 249(18.8) | 7(0.5) | 94(7.1) | 1 079(81.3) | 846(63.7)c | 253(19.1) | 682(51.4) | 764(57.5) | 51(3.9) | 12(0.9) | |||
>75岁组 | 552(27.7) | 11(0.6) | 114(5.7) | 1 483(74.4) | 1 149(57.7)c | 277(14.0) | 1 382(69.4) | 1 017(51.1) | 68(3.4) | 10(0.5) | |||
检验统计量值 | 99.273 | 0.746 | 13.776 | 54.093 | 30.931 | 48.156 | 155.025 | 93.955 | 7.682 | 7.628 | |||
P值 | <0.001 | 0.689 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.021 | 0.022 |
Table 1 Comparison of baseline data between different age groups of patients with AF and HF
组别 | 例数 | 男性〔n(%)〕 | 合并基础疾病〔n(%)〕 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
冠心病 | 高血压 | 糖尿病 | 左心室肥厚 | 心肌病 | 肝功能不全 | 慢性肾脏病 | 周围动脉疾病 | 贫血 | 甲状腺功能亢进症 | 慢性阻塞性肺疾病 | |||
<65岁组 | 691 | 332(48.0)b | 218(31.5)b | 212(30.7)b | 107(15.5) | 76(11.0) | 87(12.6) | 16(2.3) | 49(7.1)b | 8(1.2)b | 34(4.9)b | 49(7.1) | 45(6.5)b |
65~75岁组 | 1 328 | 616(46.4)b | 825(62.1)b | 640(48.2)b | 241(18.1) | 232(17.5) | 95(7.2)c | 29(2.2) | 116(8.7)b | 22(1.7)b | 70(5.3)b | 35(2.6) | 191(14.4)b |
>75岁组 | 1 992 | 784(39.4) | 1 567(78.7) | 1 195(60.0) | 352(17.7) | 497(24.9) | 29(1.5)c | 24(1.2) | 278(14.0) | 77(3.9) | 213(10.7) | 34(1.7) | 381(19.1) |
检验统计量值 | 24.095 | 508.676 | 182.784 | 2.368 | 70.613 | 141.901 | 6.266 | 35.387 | 22.302 | 42.383 | 52.742 | 64.241 | |
P值 | <0.001 | <0.001 | <0.001 | 0.306 | <0.001 | <0.001 | 0.044 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 瓣膜性心房颤动〔n(%)〕 | 心房颤动类型〔n(%)〕 | 心功能分级〔n(%)〕 | CHA2DS2-VASc评分( | HAS-BLED评分( | LAD( | |||||||
阵发性心房颤动 | 持续性心房颤动 | 长程持续性心房颤动 | 心功能Ⅱ级 | 心功能Ⅲ~Ⅳ级 | |||||||||
<65岁组 | 273(39.5) | 125(18.1) | 405(58.6) | 161(23.3) | 175(25.4) | 516(74.6) | 2.28±1.09 | 0.72±0.81 | 42.42±7.90b | ||||
65~75岁组 | 268(20.2)c | 229(17.2) | 772(58.1) | 327(24.6) | 356(26.8) | 972(73.2) | 3.59±1.18 | 1.86±0.83 | 44.73±9.40b | ||||
>75岁组 | 124(6.2)c | 396(19.9) | 1 066(53.5) | 530(26.6) | 421(21.1) | 1 571(78.8) | 4.75±1.19 | 1.98±0.83 | 47.95±10.97 | ||||
检验统计量值 | 429.531 | 9.903 | 15.332 | 1234.844a | 632.185a | 97.334a | |||||||
P值 | <0.001 | 0.042 | 0.001 | <0.001 | <0.001 | <0.001 | |||||||
组别 | LVIDd( | LVEF( | 心力衰竭类型〔n(%)〕 | 华法林〔n(%)〕 | NOAC | 阿司匹林〔n(%)〕 | |||||||
HFrEF | HFmrEF | HFpEF | 达比加群〔n(%)〕 | 利伐沙班〔n(%)〕 | |||||||||
<65岁组 | 46.48±9.59 | 51.85±12.92 | 140(20.3) | 156(22.5) | 395(57.2)b | 386(55.9) | 22(3.2) | 30(4.3) | 76(11.0) | ||||
65~75岁组 | 49.83±9.91 | 52.60±12.50 | 221(16.6) | 297(22.4) | 810(61.0)b | 563(42.4)c | 61(4.6) | 55(4.1) | 236(17.8) | ||||
>75岁组 | 51.52±10.45 | 56.11±10.86 | 171(8.6) | 369(18.5) | 1 452(72.9) | 567(28.5)c | 99(5.0) | 108(5.4) | 351(17.6) | ||||
检验统计量值 | 82.112a | 51.890a | 404.542 | 181.650 | 3.793 | 3.254 | 18.523 | ||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.150 | 0.197 | <0.001 | ||||||
组别 | 氯吡格雷〔n(%)〕 | 其他抗血小板药物〔n(%)〕 | 双联抗血小板〔n(%)〕 | 心室率控制药物〔n(%)〕 | β-受体阻滞剂〔n(%)〕 | 地高辛〔n(%)〕 | ARB/ACEI类〔n(%)〕 | 他汀类〔n(%)〕 | 转律治疗〔n(%)〕 | 导管消融〔n(%)〕 | |||
<65岁组 | 73(10.6) | 2(0.3) | 21(3.0) | 600(86.8) | 476(68.9) | 174(25.2) | 332(48.1) | 241(34.9) | 40(5.8) | 11(1.6) | |||
65~75岁组 | 249(18.8) | 7(0.5) | 94(7.1) | 1 079(81.3) | 846(63.7)c | 253(19.1) | 682(51.4) | 764(57.5) | 51(3.9) | 12(0.9) | |||
>75岁组 | 552(27.7) | 11(0.6) | 114(5.7) | 1 483(74.4) | 1 149(57.7)c | 277(14.0) | 1 382(69.4) | 1 017(51.1) | 68(3.4) | 10(0.5) | |||
检验统计量值 | 99.273 | 0.746 | 13.776 | 54.093 | 30.931 | 48.156 | 155.025 | 93.955 | 7.682 | 7.628 | |||
P值 | <0.001 | 0.689 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.021 | 0.022 |
组别 | 例数 | 男性〔n(%)〕 | 年龄( | 合并疾病〔n(%)〕 | 心功能分级〔n(%)〕 | CHA2DS2-VASc评分( | HAS-BLED评分( | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
冠心病 | 高血压 | 糖尿病 | 心功能Ⅱ级 | 心功能Ⅲ级 | 心功能Ⅳ级 | ||||||
二级医院 | 1 519 | 657(43.3) | 74.4±10.2 | 1 091(71.8) | 838(55.2) | 270(17.8) | 451(29.7) | 882(58.1) | 186(12.2) | 3.95±1.52 | 1.74±0.89 |
三级医院 | 2 492 | 1 075(43.1) | 73.7±10.8 | 1 519(61.0) | 1 209(48.5) | 430(17.3) | 501(20.1) | 1 398(56.1) | 593(23.8) | 3.94±1.52 | 1.71±0.98 |
检验统计量值 | 0.005 | -2.210a | 49.048 | 16.714 | 0.177 | 102.018 | -0.350a | -0.788a | |||
P值 | 0.944 | 0.027 | <0.001 | <0.001 | 0.674 | <0.001 | 0.726 | 0.431 | |||
组别 | LAD( | LVIDd( | LVEF( | 心力衰竭类型〔n(%)〕 | 抗凝〔n(%)〕 | 华法林〔n(%)〕 | NOAC | ||||
HFrEF | HFmrEF | HFpEF | 达比加群〔n(%)〕 | 利伐沙班〔n(%)〕 | |||||||
二级医院 | 44.03±9.11 | 47.43±11.78 | 54.71±11.24 | 174(11.5) | 1 050(69.1) | 295(19.4) | 557(36.7) | 485(31.9) | 52(3.4) | 20(1.3) | |
三级医院 | 44.17±9.27 | 49.01±8.88 | 53.93±12.35 | 358(14.4) | 1 606(64.4) | 528(21.2) | 1 334(53.5) | 1 031(41.4) | 130(5.2) | 173(6.9) | |
检验统计量值 | 0.465a | 4.337a | -2.062a | 10.585 | 107.689 | 35.798 | 7.007 | 132.556 | |||
P值 | 0.642 | <0.001 | 0.039 | 0.005 | <0.001 | <0.001 | 0.008 | <0.001 | |||
组别 | 抗血小板〔n(%)〕 | 心室率控制药物〔n(%)〕 | β-受体阻滞剂〔n(%)〕 | 地高辛〔n(%)〕 | ACEI/ARB类〔n(%)〕] | 他汀类〔n(%)〕 | 转律治疗〔n(%)〕 | 导管消融〔n(%)〕 | ICD〔n(%)〕 | 栓塞事件〔n(%)〕 | 出血事件〔n(%)〕 |
二级医院 | 761(50.1) | 1 185(78.0) | 937(61.7) | 213(14.0) | 732(48.2) | 951(62.6) | 52(3.4) | 7(0.4) | 0 | 170(11.2) | 52(3.4) |
三级医院 | 1 026(41.2) | 1 977(79.3) | 1 576(63.2) | 491(19.7) | 1 299(52.1) | 1 436(57.6) | 107(4.3) | 26(1.0) | 21(0.8) | 361(15.5) | 124(5.0) |
检验统计量值 | 30.445 | 0.988 | 0.978 | 21.045 | 5.852 | 9.724 | 1.878 | 3.925 | — | 8.919 | 5.423 |
P值 | <0.001 | 0.320 | 0.323 | <0.001 | 0.016 | 0.002 | 0.171 | <0.047 | — | 0.003 | 0.020 |
Table 2 Comparison of baseline characteristics of patients with AF andHF hospitalized insecondaryand tertiaryhospitals
组别 | 例数 | 男性〔n(%)〕 | 年龄( | 合并疾病〔n(%)〕 | 心功能分级〔n(%)〕 | CHA2DS2-VASc评分( | HAS-BLED评分( | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
冠心病 | 高血压 | 糖尿病 | 心功能Ⅱ级 | 心功能Ⅲ级 | 心功能Ⅳ级 | ||||||
二级医院 | 1 519 | 657(43.3) | 74.4±10.2 | 1 091(71.8) | 838(55.2) | 270(17.8) | 451(29.7) | 882(58.1) | 186(12.2) | 3.95±1.52 | 1.74±0.89 |
三级医院 | 2 492 | 1 075(43.1) | 73.7±10.8 | 1 519(61.0) | 1 209(48.5) | 430(17.3) | 501(20.1) | 1 398(56.1) | 593(23.8) | 3.94±1.52 | 1.71±0.98 |
检验统计量值 | 0.005 | -2.210a | 49.048 | 16.714 | 0.177 | 102.018 | -0.350a | -0.788a | |||
P值 | 0.944 | 0.027 | <0.001 | <0.001 | 0.674 | <0.001 | 0.726 | 0.431 | |||
组别 | LAD( | LVIDd( | LVEF( | 心力衰竭类型〔n(%)〕 | 抗凝〔n(%)〕 | 华法林〔n(%)〕 | NOAC | ||||
HFrEF | HFmrEF | HFpEF | 达比加群〔n(%)〕 | 利伐沙班〔n(%)〕 | |||||||
二级医院 | 44.03±9.11 | 47.43±11.78 | 54.71±11.24 | 174(11.5) | 1 050(69.1) | 295(19.4) | 557(36.7) | 485(31.9) | 52(3.4) | 20(1.3) | |
三级医院 | 44.17±9.27 | 49.01±8.88 | 53.93±12.35 | 358(14.4) | 1 606(64.4) | 528(21.2) | 1 334(53.5) | 1 031(41.4) | 130(5.2) | 173(6.9) | |
检验统计量值 | 0.465a | 4.337a | -2.062a | 10.585 | 107.689 | 35.798 | 7.007 | 132.556 | |||
P值 | 0.642 | <0.001 | 0.039 | 0.005 | <0.001 | <0.001 | 0.008 | <0.001 | |||
组别 | 抗血小板〔n(%)〕 | 心室率控制药物〔n(%)〕 | β-受体阻滞剂〔n(%)〕 | 地高辛〔n(%)〕 | ACEI/ARB类〔n(%)〕] | 他汀类〔n(%)〕 | 转律治疗〔n(%)〕 | 导管消融〔n(%)〕 | ICD〔n(%)〕 | 栓塞事件〔n(%)〕 | 出血事件〔n(%)〕 |
二级医院 | 761(50.1) | 1 185(78.0) | 937(61.7) | 213(14.0) | 732(48.2) | 951(62.6) | 52(3.4) | 7(0.4) | 0 | 170(11.2) | 52(3.4) |
三级医院 | 1 026(41.2) | 1 977(79.3) | 1 576(63.2) | 491(19.7) | 1 299(52.1) | 1 436(57.6) | 107(4.3) | 26(1.0) | 21(0.8) | 361(15.5) | 124(5.0) |
检验统计量值 | 30.445 | 0.988 | 0.978 | 21.045 | 5.852 | 9.724 | 1.878 | 3.925 | — | 8.919 | 5.423 |
P值 | <0.001 | 0.320 | 0.323 | <0.001 | 0.016 | 0.002 | 0.171 | <0.047 | — | 0.003 | 0.020 |
[1] |
郭豫涛. 中国老年心房颤动临床流行病学和抗栓管理现状及变化[J]. 中华老年心脑血管病杂志,2017,19(9):988-990. DOI:10.3969/j.issn.1009-0126.2017.09.024.
|
[2] |
|
[3] |
|
[4] |
|
[5] |
孙艺红,胡大一. 非瓣膜病心房颤动患者全球抗凝注册研究中国亚组基线数据分析[J]. 中华心血管病杂志,2014,42(10):846-850. DOI:10.3760/cma.j.issn.0253-3758.2014.10.011.
|
[6] |
宋文豪,干学东,张琳,等. 非瓣膜性心房颤动患者抗凝治疗现状和影响因素[J]. 武汉大学学报(医学版),2020,41(3):464-467. DOI:10.14188/j.1671-8852.2019.0710.
|
[7] |
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789. DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004.
|
[8] |
|
[9] |
|
[10] |
黄从新,张澍,黄德嘉,等. 心房颤动:目前的认识和治疗的建议-2018[J]. 中国心脏起搏与心电生理杂志,2018,32(4):315-368. DOI:10.13333/j.cnki.cjcpe.2018.04.001.
|
[11] |
|
[12] |
周自强,胡大一,陈捷,等. 中国心房颤动现状的流行病学研究[J]. 中华内科杂志,2004,43(7):491-494. DOI: 10.3760/j.issn:0578-1426.2004.07.005.
|
[13] |
胡大一,孙艺红,周自强,等. 中国人非瓣膜性心房颤动脑卒中危险因素的病例-对照研究[J]. 中华内科杂志,2003,42(3):157-161. DOI:10.3760/j.issn:0578-1426.2003.03.004.
|
[14] |
|
[15] |
|
[16] |
王华,李莹莹,柴坷,等. 中国住院心力衰竭患者流行病学及治疗现状[J]. 中华心血管病杂志,2019,47(11):865-874. DOI:10.3760/cma.j.issn.0253-3758.2019.11.004.
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
胡志成,蒋超,郑黎晖,等. 2019年中国心房颤动医疗质量控制报告[J]. 中国循环杂志,2020,35(5):427-437. DOI: 10.3969/j.issn.1000-3614.2020.05.003.
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[38] |
闫静静,秦明照. 中国老年心房颤动患者抗凝治疗现状及分析[J]. 中国全科医学,2018,21(27):3285-3289. DOI:10.12114/j.issn.1007-9572.2018.00.079.
|
[39] |
|
[1] | ZHANG Yuan, HOU Qiqi, QI Qi, JIANG Yue, WANG Nan, YUE Bocheng, CHEN Shuohua, HAN Quanle, WU Shouling, LI Kangbo. Relationship between Cardiovascular Health Score of Life's Essential 8 and New-onset Atrial Fibrillation: a Large Sample, Long-Term Follow-up Study [J]. Chinese General Practice, 2024, 27(12): 1431-1437. |
[2] | SHI Yushuang, WANG Huihua, LI Yan, LU Ping, SONG Wei, PAN Guijun. Analysis of the Effectiveness of Different Atrial Fibrillation Screening Methods in the Community-based Elderly Population [J]. Chinese General Practice, 2024, 27(11): 1316-1319. |
[3] | LI Xing, YANG Yining. Prevalence of Hyperuricemia and Its Correlation with Cardiometabolic Index in Xinjiang Region [J]. Chinese General Practice, 2024, 27(09): 1095-1101. |
[4] | ZHOU Luling, LIU Suzhen, LI Hang. Investigation on the Situation of Primary Health Care Institutions and Home-based Medical Service in Sichuan Province [J]. Chinese General Practice, 2024, 27(04): 433-439. |
[5] | FAN Caixia, LI Jiao, WEI Yanjin, GUO Dequn, LIU Cunfei, LI Zhengrong, QIU Shi. Influencing Factors of Overanticoagulation at Initial Stage of Warfarin Anticoagulation Therapy in Patients with Atrial Fibrillation [J]. Chinese General Practice, 2024, 27(03): 308-314. |
[6] | HE Youkuan, CAO Yong, LIN Fei, OU Yuanyuan, LI Kewen, DENG Li. Platelet Changes during Extracorporeal Membrane Oxygenation in Patients with Different Modes of Support: a Retrospective Cohort Study [J]. Chinese General Practice, 2024, 27(02): 163-167. |
[7] | WANG Jie, SUN Guozhen, BAO Zhipeng, WANG Lin, GAO Min, LIU Shenxinyu, YU Tianxi, WANG Qin, GAO Rongrong. Development Trajectory and Predictors of Strength-duration Adherence to Home-based Exercise Rehabilitation among Patients with Atrial Fibrillation after Radiofrequency Catheter Ablation: a Longitudinal Study [J]. Chinese General Practice, 2024, 27(02): 168-176. |
[8] | WANG Ruijie, LI Hongyu, SHI Hong. Association of Tooth Loss with Hearing Impairment in Chinese Older Adults Aged 65 Years and Above [J]. Chinese General Practice, 2024, 27(01): 45-50. |
[9] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[10] | LIU Puqing, CHEN Jingwen, SHOU Zhangxuan. Evaluation of Potentially Inappropriate Medication of Direct Oral Anticoagulant in Hospitalized Elderly Patients with Non-valvular Atrial Fibrillation Based on Beers Criteria [J]. Chinese General Practice, 2023, 26(35): 4388-4393. |
[11] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[12] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
[13] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[14] | MA Yanyan, REN Fuxian, WANG Yu, GAO Dengfeng. The Prediction Value of (Neutrophil+Monocyte) /Lymphocyte Ratio on In-hospital Mortality of Heart Failure Patients [J]. Chinese General Practice, 2023, 26(30): 3791-3796. |
[15] | ZHANG Zhendong, CAI Bin, WANG Hongwei, QIAO Zengyong. Study on the Changes of Intestinal Flora and Its Metabolite Phenylacetylglutamine in Patients with Chronic Heart Failure [J]. Chinese General Practice, 2023, 26(29): 3665-3673. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||